Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29257676 | 0.83 | BCHE (0.38) | BCHECA1CA2CA9MAPK1 | |
| SCHEMBL29367391 | 0.83 | BCHE (0.38) | BCHECA1CA2CA9MAPK1 | |
| SCHEMBL17724860 | 0.79 | ADORA3 (0.39) | HTTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL17725035 | 0.72 | HSPB1 (0.41) | ALDH1A1LMNAMEN1KMT2AHSPB1 | |
| SCHEMBL21345766 | 0.71 | BCHE (0.36) | BCHE | |
| SCHEMBL11509206 | 0.71 | BCHE (0.42) | ALDH1A1MAPTBCHECA1CA2 | |
| SCHEMBL12875556 | 0.71 | BCHE (0.42) | ALDH1A1MAPTBCHECA1CA2 | |
| SCHEMBL29671025 | 0.70 | BCHE (0.42) | ALDH1A1BCHECA1CA2CA9 | |
| SCHEMBL31243189 | 0.69 | RECQL (0.38) | HTTMEN1KMT2AMAPK1POLB | |
| SCHEMBL18895884 | 0.68 | BCHE (0.40) | BCHECA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3214090-B1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORP (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-10385089-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | FUJIFILM CORPORATION (JP) | 2019-08-20 | — | — | US | disclosed |
| US-10385089-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | FUJIFILM CORPORATION (JP) | 2019-08-20 | — | — | US | disclosed |
| US-20180319834-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2018-11-08 | — | — | US | disclosed |
| US-10059734-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | FUJIFILM CORPORATION (JP) | 2018-08-28 | — | — | US | disclosed |
| EP-3214090-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | Fujifilm Corporation (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
| WO-2016068341-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | 富士フイルム株式会社 | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319834-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | SLC11A2, RNASE1, KRAS | HTT 922/4885ALDH1A1 2541/4885LMNA 4093/4885 |
| US-10385089-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | SLC11A2, RNASE1, KRAS | HTT 922/4885ALDH1A1 2541/4885LMNA 4093/4885 |
| US-10059734-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | SLC11A2, RNASE1, TYMP | HTT 1309/4885ALDH1A1 1881/4885LMNA 4144/4885 |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | SLC11A2, RNASE1, TYMP | HTT 1309/4885ALDH1A1 1881/4885LMNA 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.